No abstract available.
Hamartoma*

No abstract available.
Pemphigus

No abstract available.
Mycobacterium* ; Skin*

No abstract available.
Humans ; Papilloma* ; Warts*

No abstract available.
Clonorchiasis* ; Clonorchis sinensis

Hyperglycemia during chemotherapy occurs in approximately 10% to 30% of patients. Glucocorticoids and L-asparaginase are well known to cause acute hyperglycemia during chemotherapy. Long-term hyperglycemia is also frequently observed, especially in patients with hematologic malignancies treated with L-asparaginase-based regimens and total body irradiation. Glucocorticoid-induced hyperglycemia often develops because of increased insulin resistance, diminished insulin secretion, and exaggerated hepatic glucose output. Screening strategies for this condition include random glucose testing, hemoglobin A1c testing, oral glucose loading, and fasting plasma glucose screens. The management of hyperglycemia starts with insulin or sulfonylurea, depending on the type, dose, and delivery of the glucocorticoid formulation. Mammalian target of rapamycin (mTOR) inhibitors are associated with a high incidence of hyperglycemia, ranging from 13% to 50%. Immunotherapy, such as anti-programmed death 1 (PD-1) antibody treatment, induces hyperglycemia with a prevalence of 0.1%. The proposed mechanism of immunotherapy-induced hyperglycemia is an autoimmune process (insulitis). Withdrawal of the PD-1 inhibitor is the primary treatment for severe hyperglycemia. The efficacy of glucocorticoid therapy is not fully established and the decision to resume PD-1 inhibitor therapy depends on the severity of the hyperglycemia. Diabetic patients should achieve optimized glycemic control before initiating treatment, and glucose levels should be monitored periodically in patients initiating mTOR inhibitor or PD-1 inhibitor therapy. With regard to hyperglycemia caused by anti-cancer therapy, frequent monitoring and proper management are important for promoting the efficacy of anti-cancer therapy and improving patients' quality of life.
Blood Glucose ; Drug Therapy ; Fasting ; Glucocorticoids ; Glucose ; Hematologic Neoplasms ; Humans ; Hyperglycemia* ; Immunotherapy ; Incidence ; Insulin ; Insulin Resistance ; Mass Screening ; Prevalence ; Quality of Life ; Sirolimus ; Whole-Body Irradiation

BACKGROUND: Although several traditional treatments have been applied for recalcitrant viral warts, these treatments have rarely resulted in complete recovery. To treat the recalcitrant viral wart, alternative therapies are required. OBJECTIVE: This study aimed to evaluate the efficacy and safety of quadrivalent HPV vaccine for recalcitrant wart treatment. METHODS: From 2012 to 2014, 17 patients who provided informed consent were enrolled. All patients received 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months, respectively. During clinic visits, doctors checked the grade of improvement, patient satisfaction, and treatment side effects. After completion of the 3 doses, the patients were followed up for 5 months with outpatient visits and telephone inquiries. RESULTS: After the third dose, 58.8% of patients showed complete remission and 41.2% showed no response after 5 months. There were no statistically significant differences in sex, age, disease duration, number, anatomic site, and previous treatment between the complete remission group and the no-response group. An adverse effect (syncope) was observed in one patient. CONCLUSION: Compared with traditional aggressive therapies, quadrivalent HPV vaccine is a simple method and does not usually interfere with the patient's work or social life. Quadrivalent HPV vaccine is an effective and safe alternative treatment for recalcitrant warts.
Ambulatory Care ; Clinical Study* ; Complementary Therapies ; Humans* ; Informed Consent ; Methods ; Outpatients ; Papillomaviridae* ; Patient Satisfaction ; Telephone ; Warts*

Eccrine syringofibroadenoma (ESFA) is a rare, benign adnexal neoplasm of eccrine differentiation. It is typically located on the limbs and presents as a plaque or a solitary hyperkeratotic nodule in an adult. However, there are several clinical subtypes, ranging from a solitary papule or nodule to multiple lesions with linear or diffuse distribution. Despite the diverse clinical presentation, ESFA is histologically similar. It commonly shows proliferation of anastomosing cords and strands of cuboidal epithelial cells with or without lumina embedded in a fibrovascular stroma. Herein, we report an unusual case of ESFA with verrucous surfaced plaque present on the scalp since birth in a 22-year-old man.
Adult ; Epithelial Cells ; Extremities ; Humans ; Nevus* ; Parturition ; Scalp ; Young Adult

PURPOSE: We report our initial experience with hand-assisted laparoscopic donor nephrectomy (HALDN) and compare it to our results with open donor nephrectomy (ODN). MATERIALS AND METHODS: Using the medical records of consecutive, renal, living donor-recipient pairs, 60 HALDN patients were compared with 19 ODN patients. In addition, the HALDN group was divided into two groups, initial HALDNs (n=20) and late HALDNs (n=40), for consideration of the surgeons' learning curve. RESULTS: Except 1 case of open conversion, 59 patients underwent HALDN successfully. Mean operation times were 202, 255, and 201 minutes for ODNs, initial HALDNs, and late HALDNs respectively. Mean warm ischemic time decreased from 4.5 minutes in the initial HALDNs to 3.1 minutes in the late HALDNs. Major intraoperative complications included 1 transfusion in the ODNs, 1 open conversion and 1 transfusion in the initial HALDNs, but none in the late HALDNs. Mean hospital stay decreased from 6.4 days in the ODNs to 4.6 and 3.8 days in the initial and late HALDNs, respectively. Mean analgesic use decreased from 403mg and 323mg in ODNs and initial HALDNs, respectively, to 219mg in late HALDNs. Serum creatinine levels of the recipients on post operation days 7 and 30 showed no differences among the three groups. CONCLUSIONS: All but one, HALDNs resulted in a safe donor operation with a kidney of excellent quality. The length of hospital stay and postoperative analgesic use were decreased. The cosmetic result was enhanced. Additionally, the number of living donors can be potentially increased.
Creatinine ; Humans ; Intraoperative Complications ; Kidney ; Laparoscopy ; Learning Curve ; Length of Stay ; Living Donors ; Medical Records ; Nephrectomy* ; Tissue Donors* ; Warm Ischemia

Fetal bilateral renal agenesis is a lethal congenital anomaly. An early and reliable prenatal diagnosis is extremely important as it may offer options for pregnancy termination as early as possible. The criteria for the ultrasonographic diagnosis of bilateral renal agenesis are severe oligohydramnios, nonvisualization of the bladder, and the empty renal fossae. However, severe oligohydramnios makes it difficult to diagnose the disease because of poor sonographic resolution. We present a case of fetal bilateral renal agenesis diagnosed by ultrasonography after amnioinfusion at 19 weeks gestation.
Diagnosis ; Female ; Oligohydramnios ; Pregnancy ; Prenatal Diagnosis ; Ultrasonography ; Ultrasonography, Prenatal* ; Urinary Bladder